SUPNSUPERNUS PHARMACEUTICALS, INC.vs its industry peers
A metric-by-metric comparison of SUPERNUS PHARMACEUTICALS, INC. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPNEsta | $1.6B#8 | — | 1.5x#3 | 2.3x#2 | 8.6%#10 | -152.2%#13 | -8.7%#6 | -3.6%#7 | -4.8%#5 | — | -9.7%#9 | — |
| AGIO | $1.9B#2 | — | 1.8x#4 | 34.5x#10 | 48.0%#6 | -161.3%#14 | -873.9%#11 | -40.3%#10 | — | — | -22.2%#10 | — |
| ZBIO | $1.8B#3 | — | 7.5x#10 | 184.9x#11 | 100.0%#5 | -140.6%#12 | -3830.6%#12 | -152.9%#15 | -296.6%#7 | — | -9.2%#8 | — |
| SLS | $1.8B#4 | — | 13.0x#12 | — | -100.0%#13 | 13.0%#7 | — | -19.5%#9 | — | — | 392.8%#1 | — |
| GENB | $1.8B#5 | — | 3.9x#7 | — | — | — | — | 0.0%#4 | — | — | — | — |
| STOK | $1.8B#6 | — | 5.0x#8 | 9.6x#6 | 404.5%#2 | 92.3%#4 | -11.2%#7 | -2.0%#6 | — | — | 3.4%#6 | — |
| TRAX | $1.9B#1 | — | 12.9x#11 | — | — | -1.5%#9 | — | -110.0%#13 | — | — | — | — |
| NUVB | $1.6B#7 | — | 6.5x#9 | 26.2x#8 | 699.0%#1 | 64.0%#6 | -338.7%#9 | -80.6%#12 | -87.4%#6 | — | -9.0%#7 | — |
| RARE | $1.6B#9 | — | — | 2.4x#3 | 20.2%#8 | -1.1%#8 | -79.5%#8 | — | — | — | -50.3%#13 | — |
| KLRA | $1.6B#10 | — | 1.5x#2 | — | — | — | — | 0.0%#4 | — | — | — | — |
| ANIP | — | 15.7x#3 | — | — | 43.8%#7 | 510.5%#2 | 12.6%#3 | 13.1%#2 | 16.9%#1 | — | -23.1%#11 | — |
| INVA | $1.5B#11 | 4.9x#1 | 1.2x#1 | 3.7x#4 | 14.7%#9 | 1059.2%#1 | 39.8%#2 | 22.0%#1 | 14.7%#2 | 5#1 | 15.7%#5 | — |
| OCUL | $1.5B#12 | — | 2.9x#6 | 28.9x#9 | -18.5%#12 | -37.4%#11 | -519.8%#10 | -51.1%#11 | — | — | -40.0%#12 | — |
| ETON | $1.5B#13 | — | 31.3x#13 | 18.2x#7 | 104.9%#4 | -20.4%#10 | -1.1%#5 | -9.9%#8 | -1.8%#4 | 4#2 | 184.3%#2 | — |
| PCRX | $1.5B#14 | 104.0x#4 | 2.2x#5 | 2.0x#1 | 3.6%#11 | 107.0%#3 | 2.6%#4 | 1.0%#3 | 1.0%#3 | — | 64.1%#3 | — |
| ANAB | $1.4B#15 | 8.5x#2 | 135.0x#14 | 6.1x#5 | 157.0%#3 | 90.9%#5 | 96.7%#1 | -125.0%#14 | — | — | 32.6%#4 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice